Information for Healthcare Professionals and other Stakeholders NEPHROGENIC SYSTEMIC FIBROSIS: AN UNCOMMON AND DEBILITATING DISEASE POSSIBLY ASSOCIATED WITH GADOLINIUM CHELATES Any significant information (eg publication of results of a new study, results of the investigation of a pharmacovigilance case) may cause the issue of a new version of this document. What is Nephro
PO BOX 25067
COLUMBIA, SC 29224-5067
Telephone: 803-788-9494 Fax: 803-788-9419
MATERIAL SAFETY DATA SHEET
Transportation Emergency: 800-451-8346
1. Product Identification
CAS Registry Number
131 Pontiac Business Center DriveElgin, SC 29045USA Telephone/Fax
2. Composition, Information or Ingredients
3. Hazard Identification
Avoid prolonged exposure.
Do Not breathe vapor.
Use caution when handling.
Exposure to any chemical should be limited.
To the best of our knowledge, the health hazards of this product have not been fully This product is provided solely for the purpose of research and development.
4. First Aid Measures
Check for and remove any contact lenses. Immediately flush eyes with clean, running water for at least 15 minutes while keeping eyes open. Cool water may be used. Seek medical attention.
After contact with skin, wash with generous quantities of running water. Gently and thoroughly wash affected area with running water and non-abrasive soap. Cool water may be used. Cover the affected area with emollient. Seek medical attention. Wash any contaminated clothing prior to reusing.
Remove the victim from the source of exposure to fresh, uncontaminated air. If victim's breathing is difficult, administer oxygen. Seek medical attention.
Do NOT induce vomiting. Give water to victim to drink. Seek medical attention.
5. Fire-Fighting Measures
Carbon dioxide, dry chemical powder, alcohol or polymer foam.
Special fire fighting
Wear self-contained breathing apparatus and protective clothing to prevent contact with skin and eyes.
Unusual fire and
Emits toxic fumes under fire conditions.
6. Accidental Release Measures
Steps to be taken if material is spilled or otherwise released into the environment - Wear Appropriate respirator, impervious boots and heavy rubber (or otherwise impervious) gloves. Scoop up solid material or absorb liquid material and place into appropriate container. Ventilate area and wash affected spill area after pickup is complete. Wash skin immediately with plenty of water. Place solid or absorbed material into containers and close for disposal.
7. Handling and Storage
Do not breath dust or vapor.
Have safety shower and eye wash available.
Do not get in eyes, on skin or on clothing.
Keep container tightly closed.
Store in a cool, dry, well-ventilated place.
Ensure adequate ventilation during use.
Use only in a chemical fume hood.
8. Exposure Controls and Personal Protection
Wear Protective safety goggles.
Wear chemical-resistant gloves.
Wear protective clothing and chemical resistant boots.
Ensure ventilation during use.
After contact with skin, wash immediately.
9. Physical and Chemical Properties
10. Stability and Reactivity
Strong oxidizing agentsStrong acids and bases Hazard Decomposition Products
11. Toxicological Information
May be harmful by ingestion and inhalation.
Material is irritating to mucous membranes and upper respiratory tract.
To the best of our knowledge, the toxicological properties of this product have not been fully
12. Ecological Information
Other adverse effects:
13. Disposal Considerations
Absent other actions demanded by federal or local regulations - Dissolve or mix the material with a combustible solvent and burn in a requlated, chemical incinerator equipped with after burner and scrubber.
Observe all federal, state and local laws.
14. Transport Information
15. Regulatory Information
Adhere to all Federal, State and local regulations.
16. Other Information
The information contained herein is accurate to the best of our knowledge, but is not meant to be complete and is included only as a guide. The end user is responsible for any damage resulting from handling or from contact with this product.
Economic Evaluation of ASCOT-BPLA: Antihypertensive treatment with an amlodipine-based regimen is cost-effective compared to an atenolol-based regimen Peter Lindgren, Martin Buxton, Thomas Kahan, et al. Updated information and services can be found at: Published online October 4, 2007 in advance of the print journal. Email alerting Receive free email alerts when new articles cite this